Clinical Trials Logo
  1. Home
  2. Pneumonia
  3. NCT00987792
  4. Details
NCT00987792 Clinical Trial

CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients

Pneumonia Clinical Trial

Official title:
CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00987792
Other study ID # 14522
Secondary ID AX0801
Status Completed
Phase N/A
First received September 30, 2009
Last updated August 6, 2015
Start date September 2009
Est. completion date October 2012

Study information
Verified date August 2015
Source Bayer
Contact n/a
Is FDA regulated No
Health authority Kazakhstan: Ethical CommissionMacedonia: Ministry of HealthMoldova: Ministry of HealthCroatia: Ethics CommitteeRomania: National Medicines AgencyRussia: Ethics CommitteeFrance: National Council of Physicians (CNOM)
Study type Observational

Clinical Trial Summary

The aim of this study is to obtain data from hospitalized Community Acquired Pneumonia (CAP) patients on the disease including disease severity, clinical signs and symptoms and measures used for diagnosis in daily routine practice as well as data on Avelox® including information on the use, effectiveness, treatment outcome, safety and tolerability.

As this is a non-interventional observational study, routine clinical practice is observed. The application of medications follows the normal routines and is decided by the treating physician under recognition of the package insert.

Recruitment information / eligibility
Status Completed
Enrollment 2595
Est. completion date October 2012
Est. primary completion date June 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult hospitalized patients with a diagnosis of CAP (based on local medical practice) and decision taken by the investigator to treat with moxifloxacin and to start treatment with intravenous administration. The local moxifloxacin product information must be considered.

Exclusion Criteria:

- Contraindications stated in the local moxifloxacin product information; warnings and precautions must be considered.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Intervention

Drug:
• Moxifloxacin (Avelox, BAY12-8039)
Hospitalized patients receiving Avelox according to local drug information

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Bayer

Countries where clinical trial is conducted

Croatia,  France,  Hungary,  Jordan,  Kazakhstan,  Lebanon,  Macedonia, The Former Yugoslav Republic of,  Moldova, Republic of,  Romania,  Russian Federation,  Ukraine, 

References & Publications (1)

Kuzman I, Bezlepko A, Kondova Topuzovska I, Rókusz L, Iudina L, Marschall HP, Petri T. Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI). BMC Pulm Med. 2014 Jun 30;14:105. doi: 1 — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary The primary objective is to evaluate the distribution of the CRB-65 severity index at baseline in hospitalized patients suffering from CAP and to whom moxifloxacin (starting with intravenous administration) was prescribed, in countries from South Eastern At baseline only No
Secondary Assessment of use of different diagnostic measures in daily routine practice, especially chest radiography and microbiology 7-14 days No
Secondary Determination of the proportion of patients treated with moxifloxacin as antibiotic second-line therapy 7-14 days No
Secondary Assessment of clinical signs and symptoms before and after therapy with moxifloxacin 7-14 days No
Secondary Measurement of moxifloxacin treatment success in terms of effectiveness and outcome 7-14 days No
Secondary Evaluation of safety and tolerability of moxifloxacin in hospitalized CAP patients 7-14 days Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04244474 - Effect of Vitamin D Supplementation on Improvement of Pneumonic Children Phase 1/Phase 2
Completed NCT05815264 - Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above Phase 1
Recruiting NCT04589936 - Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care N/A
Completed NCT02905383 - The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital N/A
Completed NCT06210737 - A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months，7 Months-5 Years Phase 4
Terminated NCT03944551 - Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa N/A
Terminated NCT04660084 - Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT05702788 - Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) Phase 2
Not yet recruiting NCT04171674 - Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation. N/A
Active, not recruiting NCT03140163 - Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR] N/A
Completed NCT02638649 - Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
Completed NCT02864420 - Hospitalization at Home: The Acute Care Home Hospital Program for Adults N/A
Recruiting NCT02515565 - Physiotherapy in Patients Hospitalized Due to Pneumonia. N/A
Completed NCT02105298 - Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study) N/A
Completed NCT01446926 - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants Phase 1
Completed NCT01399723 - Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia Phase 3
Completed NCT01416519 - Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation N/A
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Terminated NCT02358642 - Drug to Prevent Pneumonia in the Tube Fed Phase 4

External Links